---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-085773"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2025-04-18T23:59:59+00:00"
generated_at: "2026-05-23T10:59:07.982968+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Tempest Therapeutics cuts 21 of 26 full-time staff, initiates strategic review

## Summary
- Workforce reduced by 21 of 26 full-time employees, effective April 30, 2025.
- Estimated $1.5M in cash severance and benefit costs, mostly in Q2 2025.
- Key affected employees to transition to consulting agreements.
- Company initiated process to explore strategic alternatives to extend capital resources.

## SEC filing metadata
- accession: 0001193125-25-085773
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2025-04-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- confidence: high
- sec_items: 2.05
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/0001193125-25-085773-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312525085773/d792758d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-085773
- JSON: https://secwatch.observer/filing/0001193125-25-085773.json
- Plain text: https://secwatch.observer/filing/0001193125-25-085773.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.